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S U M M A R Y
Background: Human T-lymphotropic virus type 1 (HTLV-1) is considered to be the etiological agent of
adult T-cell leukemia/lymphoma (ATL) and HTLV-associated myelopathy/tropical spastic paraparesis
(HAM/TSP). Blood transfusion is a common transmission pathway for HTLV-1. However, no surveys to
determine the overall prevalence of HTLV-1 infection and HTLV-1 genotypes among blood donors on the
Chinese mainland have yet been conducted.
Methods: A systematic review and meta-analysis of the peer-reviewed literature on this topic was
carried out. Data manipulation and statistical analyses were performed using the Comprehensive Meta
Analysis Version 2.0 program.
Results: Forty-four eligible articles involving 458 525 blood donors were selected. Analysis revealed the
pooled prevalences of HTLV-1 infection among blood donors in Fujian and Guangdong provinces to be
9.9/10 000 (95% conﬁdence interval (CI) 4.4/10 000–22.2/10 000) and 2.9/10 000 (95% CI 1.7/10 000–4.8/
10 000), respectively; there were only two cases of HTLV-1 infection among 204 763 donors in other
areas of the Chinese mainland. In addition, 40 of 42 (95.2%) HTLV-1 isolates belonged to the
Transcontinental subgroup A of the HTLV-1 subtype A (Cosmopolitan subtype).
Conclusions: The prevalence of HTLV-1 infection among blood donors is low and restricted mainly to the
provinces of Fujian and Guangdong. Most isolates belong to the Transcontinental subgroup within HTLV-
1 subtype A.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Human T-lymphotropic virus type 1 (HTLV-1) was ﬁrst isolated
from a blood sample of a patient with cutaneous T-cell lymphoma
and identiﬁed as a retrovirus by Poiesz et al.1 HTLV-1 is considered
to be the etiological agent of adult T-cell leukemia/lymphoma
(ATL) and HTLV-associated myelopathy/tropical spastic parapar-
esis (HAM/TSP).2 Human lymphotropic virus type 2 (HTLV-2), a
closely related virus found in 1982, has no clear association with
clinical disease.3,4 HTLV-1/2 can be transmitted by transfusion of
infected cellular blood products and sexual contact, as well as
mother-to-child transmission.5–9 Initial screening assays for HTLV-
1 antibodies are generally ELISA, particle agglutination (PA), and
immunoﬂuorescence (IF) tests. Subsequent immunoblotting and
nucleic acid tests (NAT) are used to conﬁrm the presence of HTLV-1
infection.10 The World Health Organization (WHO) has advised* Corresponding author.
E-mail addresses: chenyz@mail.fjmu.edu.cn, fjsdlx@126.com (Y. Chen).
http://dx.doi.org/10.1016/j.ijid.2014.02.021
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).that decisions regarding the screening of blood donations for HTLV
be guided by local epidemiological evidence.11 So far no surveys to
determine the overall prevalence of HTLV-1 infection and HTLV-1
genotypes among blood donors have been conducted on the
Chinese mainland. Therefore, we conducted a systematic review
and meta-analysis of the available data.
2. Methods
2.1. Literature search
The literature on the prevalence and genotypes of HTLV-1 in
blood donors on the Chinese mainland was identiﬁed through
searching electronic databases (PubMed, China National Knowl-
edge Infrastructure (CNKI), and Wanfang) for the period January
1998 to June 2013. To search and include as many related studies
as possible, we used combinations of various key words, including
human T-lymphotropic virus type I(1) or HTLV-I(1), blood donor or
donation, and China or Chinese mainland. A manual search of the
reference lists of published articles was also performed. This studyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow chart of the systematic literature search process.
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(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines issued in 2009.12
2.2. Selection and data abstraction
Articles in the literature were identiﬁed and data were
extracted by two investigators, independently. Disagreements
were resolved through discussion. Studies were included if they
were: (1) full text articles in the three databases mentioned, with
no language restrictions; (2) reported the prevalence or genotypes
of HTLV-1 in blood donors on the Chinese mainland; (3) used
immunoblot assays or NAT as conﬁrmatory tests of HTLV-1
infection. Studies were excluded if they were: (1) from regions of
China other than the mainland (i.e., Hong Kong, Macao, and
Taiwan); (2) review papers or dissertations; (3) conference
abstracts or presentations. If the same study data were published
in both Chinese and English, the articles published in Chinese were
excluded from this study. The following information was extracted
from the eligible studies on HTLV-1 prevalence: ﬁrst author’s
name, year of publication, study location, sample collection period,
target population, sample size, testing method, and number of
infections.
The quality of studies on the prevalence of HTLV-1 was assessed
using a validated quality assessment tool.13 Eight items were used
to assess the quality of studies: (1) clear deﬁnition of the target
population; (2) representativeness of probability sampling; (3)
sample characteristics matching the overall population; (4)
adequate response rate; (5) standardized data collection methods;
(6) reliable survey measures; (7) valid survey measures; (8)
appropriate statistical methods. Answers were scored 0 and 1 for
‘no’ and ‘yes’, respectively. The total score varied between 0 and 8
for each study.
2.3. Statistical analysis
Data manipulation and statistical analyses were carried out
using Comprehensive Meta Analysis Version 2.0 (CMA 2.0; Biostat
Inc., Englewood, NJ, USA). To normalize the distribution of the
prevalence rate, prevalence data were transformed into logit event
rate data as follows: logit p = ln [p/(1  p)], with ln being the
natural logarithm and p the prevalence rate. The sampling variance
of each logit event rate was called V (logit p) and calculated as 1/
(np) + 1/[n(1  p)], with n being the sample size. After the statistical
analyses, the results were transformed back into prevalence rates
using the formula: p = elogit p/(elogit p + 1), with e being the base of
the natural logarithm.14 The pooled prevalence estimates and 95%
conﬁdence intervals (CI) were determined based on random or
ﬁxed effects models, taking into account the possibility of
heterogeneity between studies, which was tested using the Q test
(p < 0.10 was considered indicative of statistically signiﬁcant
heterogeneity) and I2 test (values of 25%, 50%, and 75% were
considered to represent low, medium, and high heterogeneity,
respectively). Furthermore, meta-regression was used to investi-
gate factors associated with heterogeneity. Publication bias was
also assessed by Egger’s and Begger’s tests (p < 0.05 represents
statistically signiﬁcant publication bias). In addition, the HTLV-1
genotypes of blood donors in mainland China were assessed.
3. Results
3.1. Flow of the studies through the selection process
Initially, a total of 407 studies were retrieved from the
databases using different combinations of the key search terms:
10 studies from PubMed, 286 studies from CNKI, and 111 fromWanfang. Using the inclusion and exclusion criteria, we excluded
346 studies after title and abstract screening and another 17
articles after reading the full text. Finally, 44 articles were selected,
40 articles15–54 on the prevalence of HTLV-1 and nine arti-
cles17,27,42,49,51,55–58 on the genotypes. The selection process is
illustrated in Figure 1.
3.2. Study characteristics
All forty studies on the prevalence of HTLV-1 infection were
cross-sectional; they involved 17 provinces, one autonomous
region, and three municipalities. The present analysis included
458 525 participants (198 448 from Fujian, 55 314 from Guang-
dong, and 204 763 from other areas). The blood samples mainly
came from blood banks, the Centers for Disease Control and
Prevention (CDC), and hospitals. The sample size of the selected
studies ranged from 80 to 131 823 (median 3404, interquartile
range 1402–8813). ELISA was used for laboratory screening in all
except a few studies, which also used PA (particle agglutination) or
IF (immunoﬂuorescence).15,23–25 Immunoblot assays or NAT were
used for conﬁrmation in all studies. The details of each study on the
prevalence of HTLV-1 are presented in Table 1.
3.3. Prevalence of HTLV-1 among blood donors in mainland China
A pooled estimate of HTLV-1 prevalence was obtained from an
analysis of 12 studies involving blood donors in Fujian
Province.15,17,26–28,33,39,42–44,48,49 The heterogeneity (I2 = 90.7%,
Table 1
Summary of data from selected articles on HTLV-1 prevalence among blood donors in mainland China.
First author and
year of publication
Language Study
location
Screening
tests
Conﬁrmatory
tests
Sample
collection
year(s)
Target
population
Sample size Number of
HTLV-1
infections
Quality
assessment
score
Cao F, 199815 English Fujian PA/ELISA Immunoblot NA Blood donor 1299 2 6
Sichuan PA/ELISA Immunoblot NA Blood donor 2614 0
Cao Y, 200816 Chinese Jiangsu ELISA Immunoblot 2004 Blood donor 3608 0 6
Chen CR, 201217 Chinese Fujian ELISA Immunoblot/NAT 2004–2009 Blood donor 131 823 24 7
Chen ZW, 200918 Chinese Guangdong ELISA Immunoblot 2004–2005 Blood donor 1008 0 6
Du Y, 200819 Chinese Zhejiang ELISA Immunoblot 2006–2007 Blood donor 5556 0 6
Fan WA, 200220 Chinese Anhui ELISA Immunoblot NA Blood donor 880 0 3
Fang CF, 200421 Chinese Jiangxi ELISA NT NA Blood donor 8850 0 6
Feng GJ, 200522 Chinese Shandong ELISA Immunoblot NA Blood donor 6160 0 6
Geng L, 199823 English Liaoning PA/ELISA/IF Immunoblot 1995–1997 Blood donor 1645 0 7
Guan SF, 200124 Chinese Beijing PA NT 1996 Blood donor 749 0 4
Hu J, 200325 Chinese Chongqing PA/ELISA Immunoblot NA Blood donor 1462 0 6
Huang RX, 199826 Chinese Fujian ELISA Immunoblot NA Blood donor 2100 3 6
Huang RX, 200227 Chinese Fujian ELISA Immunoblot/NAT 2000 Blood donor 10 512 1 6
Ji Y, 200028 Chinese Fujian ELISA Immunoblot 1997–1998 Blood donor 2399 3 6
Hubei ELISA Immunoblot 1997–1998 Blood donor 578 0
Shandong ELISA Immunoblot 1997–1998 Blood donor 1994 0
Xinjiang ELISA Immunoblot 1997–1998 Blood donor 1572 0
Zhejiang ELISA Immunoblot 1997–1998 Blood donor 1029 0
Jia W, 200429 Chinese Qinhai ELISA NT NA Blood donor 4529 0 5
Li J, 200830 Chinese Guangdong ELISA Immunoblot 2006–2007 Blood donor 26 608 9 6
Li RL, 200531 Chinese Tianjing ELISA Immunoblot 2002–2003 Blood donor 11 757 0 6
Li YF, 200832 Chinese Guangdong ELISA Immunoblot 2006 Blood donor 6112 0 6
Lin YS, 200433 Chinese Fujian ELISA Immunoblot/NAT 2002 Blood donor 5000 4 6
Ma Y, 201334 English Henan, Hubei ELISA Immunoblot 2008–2011 Blood donor 3548 2 7
Sun SJ, 201335 Chinese Guangdong ELISA Immunoblot 2012 Blood donor 2500 1 6
Tang Q, 200236 Chinese Jiangsu ELISA Immunoblot 2000 Blood donor 1436 0 6
Tang QP, 200737 Chinese Hainan ELISA Immunoblot NA Blood donor 11 000 0 6
Tang RC, 200338 Chinese Jiangsu ELISA NAT 2002 Blood donor 9500 0 5
Wang HR, 200439 Chinese Fujian ELISA Immunoblot 1999–2002 Blood donor 1643 1 6
Wang JQ, 200140 Chinese Zhejiang ELISA NT NA Blood donor 892 0 5
Wang WL, 199941 Chinese Beijing ELISA Immunoblot NA Blood donor 1929 0 6
Wang YC, 200542 English Fujian ELISA Immunoblot NA Blood donor 34 800 19 6
Guangdong ELISA Immunoblot NA Blood donor 5073 0
Hainan ELISA Immunoblot 2004–2005 Blood donor 12 084 0
Henan ELISA Immunoblot 2004–2005 Blood donor 14 266 0
Hubei ELISA Immunoblot 2004–2005 Blood donor 8800 0
Jiangsu ELISA Immunoblot 2004–2005 Blood donor 9500 0
Jiangxi ELISA Immunoblot 2004–2005 Blood donor 8500 0
Jilin ELISA Immunoblot 2004–2005 Blood donor 8900 0
Liaoning ELISA Immunoblot 2004–2005 Blood donor 18 300 0
Shandong ELISA Immunoblot 2004–2005 Blood donor 13 769 0
Tianjing ELISA Immunoblot 2004–2005 Blood donor 4635 0
Xinjiang ELISA Immunoblot 2004–2005 Blood donor 1820 0
Zhejiang ELISA Immunoblot 2004–2005 Blood donor 4846 0
Xue GZ, 200143 Chinese Fujian ELISA Immunoblot 1997–1998 Blood donor 252 2 5
Yin HZ, 200044 Chinese Beijing ELISA Immunoblot NA Blood donor 920 0 6
Fujian ELISA Immunoblot NA Blood donor 1056 4
Guangxi ELISA Immunoblot NA Blood donor 592 0
Jiangxi ELISA Immunoblot NA Blood donor 845 0
Yue XQ, 200545 Chinese Jilin, Liaoning,
Heilongjiang
ELISA Immunoblot 2000 Blood donor 80 0 4
Zeng JF, 200446 Chinese Guangdong ELISA Immunoblot 2002 Blood donor 3260 0 7
Zhang BW, 200347 Chinese Henan ELISA Immunoblot NA Blood donor 9074 0 6
Zhang GZ, 200248 Chinese Fujian ELISA Immunoblot/NAT 1998–2000 Blood donor 4564 16 6
Zhang QW, 200749 Chinese Fujian ELISA Immunoblot 2006 Blood donor 3000 1 6
Zhang SB, 200950 Chinese Hunan ELISA Immunoblot 2008 Blood donor 830 0 6
Zhou P, 200951 Chinese Guangdong ELISA NAT 2006–2007 Blood donor 7630 1 6
Zhou ZM, 199952 Chinese Guangxi ELISA Immunoblot NA Blood donor 868 0 6
Zhu H, 200453 Chinese Zhejiang ELISA Immunoblot 2002 Blood donor 4846 0 6
Zhuang W, 200154 Chinese Guangdong ELISA Immunoblot NA Blood donor 3123 1 6
HTLV-1, human T-lymphotropic virus type 1; ELISA, enzyme-linked immunosorbent assays; IF, immunoﬂuorescence tests; NA, not available; NAT, nucleic acid tests; NT, not
tested; PA, particle agglutination tests.
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was substantial. Therefore, a random-effects model was used to
estimate the pooled prevalence of HTLV-1 among blood donors in
Fujian. The estimate was 9.9/10 000 (95% CI 4.4/10 000–22.2/
10 000). Begger’s and Egger’s tests found no signiﬁcant publication
bias (pBegger’s test = 0.95, and pEgger’s test = 0.40) and therefore
no effect of publication bias on this estimate. In addition,meta-regression was used to estimate the effect of study factors
(publication period, sample size, and language) on the log
prevalence of the outcome. The year of publication and sample
size, but not the language of publication, contributed signiﬁcantly
to heterogeneity. The pooled prevalence of HTLV-1 was also
signiﬁcantly lower for studies published after 2005 than before
2005 (i.e., 3.2/10 000 and 16.0/10 000, respectively). Studies with
Table 2
Results of univariable meta-regression analysis of the Fujian Province dataa
Study factors No. of studies (n) Heterogeneity Pooled estimate, per 10 000, (95% CI) Meta-regression
I2 (%) p-Value b, p-value
Total 12 90.7 0 9.9 (4.4–22.2)
Period of publication
January 1998–December 2004 9 68.5 p < 0.01b 16.0 (8.2–31.1) b = 1.67
January 2005–June 2013 3 84.4 p < 0.01b 3.2 (1.3–8.0) p < 0.01b
Sample size
<5000 8 50.3 p = 0.05b 20.9 (11.7–37.1) b = 1.82
5000 4 83.2 p < 0.01b 3.4 (1.5–7.9) p < 0.01b
Language of article
Chinese 10 92.2 p < 0.01b 10.0 (3.5–28.4) b = 0.21
English 2 48.6 p = 0.16 7.4 (2.9–18.6) p = 0.82
a The pooled estimate (per 10 000), 95% conﬁdence interval (CI), number of studies (n), meta-regression coefﬁcient (b), and signiﬁcance of b (p-value) are shown.
b p-Values represent signiﬁcant associations (p < 0.10).
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prevalence than otherwise (Table 2).
With no signiﬁcant heterogeneities (I2 = 0%, p = 0.91) among
eight studies, a meta-analysis (ﬁxed-effects model) was use to
calculate the pooled estimate of HTLV-1 prevalence among blood
donors in Guangdong Province.18,30,32,35,42,46,51,54 The estimate
was 2.9/10 000 (95% CI 1.7/10 000–4.8/10 000). No signiﬁcant
publication bias was detected by Begger’s and Egger’s tests
(pBegger’s test = 1. 0, and pEgger’s test = 0.12).
Only two cases of HTLV-1 infection among 204 763 donors, one
from Henan and the other from Hubei Province, were reported in
all other areas of mainland China.34
3.4. Genotypes of HTLV-1 among infected blood donors
Nine of the studies included used phylogenetic analyses of env
and LTR (the long terminal repeat) regions to genotype 42 HTLV-1
isolates from conﬁrmed positive samples.17,27,42,49,51,55–58 The
genetic analyses showed that 40 of the 42 (95.2%) isolates
belonged to the Transcontinental subgroup A of the HTLV-1
subtype A (Cosmopolitan subtype) and two isolates (4.8%)
clustered within the Japanese subgroup B.
4. Discussion
Like several other blood-borne infectious agents (hepatitis B
virus, hepatitis C virus, and HIV), HTLV-1 has a worldwide
prevalence. It is estimated that 15 to 20 million individuals are
HTLV-1-infected.9,59 HTLV-1 prevalence is relatively high in
southwestern Japan (up to 10%),60,61 several countries in the
Caribbean area, for example Jamaica and Trinidad (up to 6%),62,63
some countries of Sub-Saharan Africa including Benin, Cameroon,
and Guinea-Bissau (up to 5%),64–67 and localized areas of Australo-
Melanesia and Iran (less than 5%),68,69 and it is somewhat lower in
several countries of South America.70–74 For blood donors in North
America and Europe, HTLV-1 prevalence is very low, i.e., 1–3/
10 000 in the USA and Canada, 0.2/10 000 in Norway, and 0.56/
10 000 in Greece.75–78 In Asia, except for some important endemic
areas including mainly Iran and Japan, the prevalence of HTLV-1
appears low.79 However, in most areas of Asia, particularly the
Chinese mainland, HTLV-1 prevalence among blood donors
remains unknown due to the lack of large and representative
studies. In addition, screening of blood donors is an effective
strategy for preventing HTLV-1 transmission. Given the high cost
of testing, a relatively accurate prevalence rate is needed for an
appropriate strategy of blood donation screening in various areas.
Hence the prevalence of HTLV-1 infection among blood donors on
the Chinese mainland was evaluated in this study.Forty articles on HTLV-1 prevalence among blood donors were
identiﬁed for this study.15–54 Most HTLV-1-infected blood donors
were reported in the provinces of Fujian and Guangdong, and only
two cases were reported in other areas of mainland China. Hence,
meta-analyses were conducted to estimate the prevalence of
HTLV-1 among blood donors in Fujian and Guangdong provinces.
The prevalence was 9.9/10 000 (95% CI 4.4/10 000–22.2/10 000) in
Fujian and 2.9/10 000 (95% CI 1.7/10 000–4.8/10 000) in Guang-
dong. These are much lower than those in southern Japan, Sub-
Saharan Africa, and the Caribbean area, and higher than those in
North America and Europe. In addition, our results suggest that the
distribution of HTLV-1-infected blood donors in mainland China is
similar to that in the rest of the world, which means clusters of
endemicity (Fujian and Guangdong) tend to occur near provinces
where the virus has not been reported previously. Generally, a low
prevalence of HTLV-1 is deﬁned as less than 1% in a speciﬁc
population.9,10 The present study found the prevalence of HTLV-1
infection among blood donors to be low in Fujian and Guangdong
provinces, and that HTLV-1 is not endemic throughout mainland
China.
Furthermore, meta-regression analysis identiﬁed publication
period and sample size to be contributors to the heterogeneity
between studies on prevalence in Fujian Province. Pooled
prevalence estimates of HTLV-1 among blood donors decreased
between the earlier (January 1998–December 2004) and later
(January 2005–June 2013) periods. Possible explanations for this
decrease include improvements in laboratory technology,
improvements in research designs, lifestyle changes, improve-
ments in sanitary conditions, etc. Our results also showed that the
prevalence of HTLV-1 among blood donors was lower in studies
with large sample sizes (5000) than in those with small sample
sizes.
Phylogenetic analysis of the env and LTR genes has detected
four main genotypes of HTLV-1: HTLV-1 subtype A (Cosmopolitan
subtype), which is distributed worldwide; HTLV-1 subtype B and
subtype D, found in Central Africa; and HTLV-1 subtype C, found in
Australo-Melanesia. Furthermore, four subgroups are distin-
guished within HTLV-1 subtype A, namely, the Transcontinental,
Japanese, West African, and North African subgroups.80 Our results
showed that the genotypes of most HTLV-1 isolates from blood
donors belonged to the Transcontinental subgroup within HTLV-1
subtype A. It would be helpful to understand the origins and
dissemination of HTLV-1 infection throughout the Chinese
mainland.
The strategies for HTLV-1 prevention and control should be
based on local epidemiological evidence. To date, however, there
are no public health policies for the prevention of HTLV-1
transmission via blood transfusions on the Chinese mainland. It
is advised that blood donors in Fujian and Guangdong provinces be
X. Li et al. / International Journal of Infectious Diseases 25 (2014) 94–9998screened for HTLV. Considering the cost of testing, more cost-
effective strategies for HTLV screening of donated blood need to be
designed and evaluated. Moreover, a surveillance system of HTLV-
1 infection should be implemented in endemic or non-endemic
areas, especially in the high population mobility areas of mainland
China.
This meta-analysis has several limitations. Of the 31 provinces
on the Chinese mainland, only 21 provinces (i.e., 17 provinces, one
autonomous region, and three municipalities) were included. No
data on the prevalence of HTLV-1 infection among blood donors
were available for all other regions. Secondly, our ability to assess
study quality was limited because many of the selected studies
failed to provide detailed information on subjects or valid data on
important factors. Thirdly, the studies included were observational
and blood donors were not chosen randomly. So confounding and
selection bias appears inevitable. Considering that the publication
of negative trials is sometimes less likely, this study also has the
potential limitation of publication bias. Additionally, most of our
data were extracted from studies written in Chinese, which makes
it difﬁcult for non-Chinese readers to refer back to the original
materials. However, we have conﬁdence in our results since most
of the articles included were from multiple sources, and pooling of
data for 458 525 blood donors provided us with a large sample size.
In summary, our study reveals that the prevalence of HTLV-1
infection among blood donors is low and restricted mainly to
Fujian and Guangdong provinces on the Chinese mainland, and the
genotypes of most HTLV-1 isolates belong to the Transcontinental
subgroup within HTLV-1 subtype A.
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